The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IWWM-12 2024 | The impact of clonal hematopoiesis on treatment strategies for Waldenström’s macroglobulinemia
Adam Sperling, MD, PhD, Dana Farber Cancer Institute, Boston, MA, discusses how the presence of clonal hematopoiesis might affect treatment strategies for patients with Waldenström’s macroglobulinemia. He emphasizes that current data is insufficient to warrant changes in therapy based on the presence of clonal hematopoiesis. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
